Medication of inclusion body myositis: A systematic review

Acta Neurologica Scandinavica

Volumn 133, Issue 2, 2016, Pages 97-102

  Saltychev, M ^a   Mikkelsson, M ^b   Laimi, K ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

Author keywords

Immunoglobulin; Inclusion body; Interferon; Myositis; Systematic review

Indexed keywords

BIMAGRUMAB; ETANERCEPT; IMMUNOGLOBULIN; INTERFERON; METHOTREXATE; OXANDROLONE;

CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECT; EVALUATION STUDY; HEALTH CARE QUALITY; HUMAN; INCLUSION BODY MYOSITIS; INFORMATION PROCESSING; INFORMATION PROCESSING BIAS; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84953637807     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12455     Document Type: Review

References (18)

1. Davenport TE, Shrader JA, McElroy B, Rakocevic G, Dalakas M, Harris-Love MO. Validity of the single limb heel raise test to predict lower extremity disablement in patients with sporadic inclusion body myositis. Disabil Rehabil 2014;36:2270-7.
2. Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008;15:1350-3.
3. Greenberg SA. Inclusion body myositis: review of recent literature. Curr Neurol Neurosci Rep 2009;9:83-9.
4. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012;78:1009-15.
5. Machado P, Brady S, Hanna MG. Update in inclusion body myositis. Curr Opin Rheumatol 2013;25:763-71.
6. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. 2011; www.cochrane-handbook.org (accessed 8 February 2015).
7. Amato AA, Sivakumar K, Goyal N et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 2014;83:2239-46.
8. Barohn RJ, Herbelin L, Kissel JT et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006;66:S123-4.
9. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-7.
10. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48:712-6.
11. Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis - a randomized pilot study. Neurology 2003;61:260-2.
12. Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002;58:1081-7.
13. Tawil R, Griggs R, Jackson C et al. Randomized pilot trial of beta INF1a (Avonex) in patients with inclusion body myositis. Neurology 2001;57:1566-70.
14. Tawil R, Griggs R, Thornton C et al. Randomized pilot trial of high-dose beta INF-1a in patients with inclusion body myositis. Neurology 2004;63:718-20.
15. Walter MC, Lochmuller H, Toepfer M et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22-8.
16. Zschüntzsch J, Voss J, Creus K et al. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle. Arthritis Rheum 2012;64:4094-103.
17. Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 2004;17:561-7.
18. Mastaglia FL, Needham M. Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches. J Clin Neurosci 2015;22:6-13.